Feasibility of HER2-Targeted Therapy in Advanced Biliary Tract Cancer: A Prospective Pilot Study of Trastuzumab Biosimilar in Combination with Gemcitabine Plus Cisplatin

SIMPLE SUMMARY: Unresectable or metastatic biliary tract cancer (BTC) has a poor prognosis with the standard gemcitabine and cisplatin (GemCis) regimen. Given the considerable incidence of HER2-overexpressing tumours (e.g., >10% of gallbladder cancer), HER2 is a potential therapeutic target in ad...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancers (Basel)
Hlavní autoři: Jeong, Hyehyun, Jeong, Jae Ho, Kim, Kyu-Pyo, Lee, Sang Soo, Oh, Dong Wook, Park, Do Hyun, Song, Tae Jun, Park, Yangsoon, Hong, Seung-Mo, Ryoo, Baek-Yeol, Yoo, Changhoon
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI 2021
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7825072/
https://ncbi.nlm.nih.gov/pubmed/33418871
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13020161
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky